Savorè C et al. reported decreased cell proliferation rate and reduced tumor size due to an inhibited response to heparin-binding growth factor and reported that perlecan is an essential ECM component involved in the tumor growth response in a prostate cancer cell line with perlecan knockdown [28]. The gene discussed is HSPG2; the disease is prostate carcinoma.